Trantelinium bromide is an anticholinergic and spasmolytic drug, used for the treatment of gastric ulcers.

1‐α‐D‐(5‐Fluoro‐5‐deoxyarabinofuranosyl)‐2‐nitroimidazole (fluoroazomycin arabinoside, FAZA) is a putative PET imaging agent when labelled with 18F. Fluoroazomycin arabinoside is essential in the generation of fluorine F 18-fluoroazomycin arabinoside (18F-FAZA), which is a radiofluorinated 2-nitroimidazole derivative with hypoxia (low oxygen)-specific tracer activity. 18F-FAZA is reduced under hypoxic conditions, forming highly reactive intermediates. In its reduced form, 18F-FAZA covalently binds to macromolecules, thereby accumulating in hypoxic cells (e.g. malignant tumors) and allowing radioisotopic imaging of these particular cells with positron emission tomography (PET).

GW-870086 (now known as GSK 870086) was developed by GlaxoSmithKline as a glucocorticoid receptor agonist. Repeat inhaled doses of GW-870086 was studied in phase II clinical trial in patients with asthma. In addition, phase II clinical trial was investigated to determine the efficacy of GW-870086 ream formulation in subjects with moderate to severe atopic dermatitis. However, the development of this drug appears to have been discontinued.

11C-NOP-1A is a new radioligand for thenociceptin/orphanin FQ peptide (NOP) receptor, with high affinity (Ki, 0.15 nM) and appropriate lipophilicity (measured logD, 3.4) for PET brain imaging. 11C-NOP-1A is the the first successful radioligand to image NOP receptors in rat and monkey brain. 11C-NOP-1A is a selective antagonist at the NOP receptor and has high affinity and appropriate lipophilicity for blood–brain barrier permeability. 11C-NOP-1A imaging in rhesus monkeys showed high brain uptake and a large receptor-specific signal and could be quantified with the gold standard method of compartmental modeling. In humans 1C-NOP-1A reliably quantified NOP receptors in human brain both in large brain regions and at a voxelwise level using parametric imaging. The radiation absorbed dose in humans was similar to that observed with other 11C-labeled ligands and would allow multiple scans of a single subject. Thus, 11C-NOP-1A is a promising radioligand for reliably quantifying NOP receptors in human brain.